EyeGene Inc (185490) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.061x

Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.13 Billion ≈ $-2.12 Million USD) by net assets (₩50.92 Billion ≈ $34.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of EyeGene Inc to measure how much of total assets are equity-financed.

EyeGene Inc - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 185490 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

EyeGene Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kaya Limited NSE:KAYA	-0.131x
Wha Yu Industrial Co Ltd TW:3419	-0.083x
Sam Jung Pulp KO:009770	0.009x
Ram-On Investments and Holdings Ltd TA:RMN	-0.002x
Centara Hotels & Resorts Leasehold Property Fund BK:CTARAF	0.025x
Regional Express Holdings Ltd AU:REX	0.063x
Information and Communication Networks Public Company Limited BK:ICN	0.114x
Romerike Sparebank OL:ROMER	-0.198x

Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see EyeGene Inc (185490) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩54.25 Billion ≈ $36.77 Million	₩-5.98 Billion ≈ $-4.05 Million	-0.110x	+54.42%
2024-12-31	₩50.32 Billion ≈ $34.10 Million	₩-12.17 Billion ≈ $-8.25 Million	-0.242x	+22.45%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	₩-20.07 Billion ≈ $-13.60 Million	-0.312x	-12.09%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	₩-18.57 Billion ≈ $-12.58 Million	-0.278x	+17.49%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	₩-30.00 Billion ≈ $-20.33 Million	-0.337x	+55.40%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	₩-9.75 Billion ≈ $-6.61 Million	-0.756x	-72.94%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	₩-8.32 Billion ≈ $-5.64 Million	-0.437x	-36.42%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	₩-7.48 Billion ≈ $-5.07 Million	-0.321x	-12.64%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	₩-6.76 Billion ≈ $-4.58 Million	-0.285x	+23.06%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	₩-5.99 Billion ≈ $-4.06 Million	-0.370x	-87.96%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	₩-4.48 Billion ≈ $-3.04 Million	-0.197x	+68.29%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	₩-2.39 Billion ≈ $-1.62 Million	-0.621x	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$45.69 Million

₩67.43 Billion KRW

Market Cap Rank

#22186 Global

#1355 in Korea

Share Price

₩1560.00

Change (1 day)

+6.19%

52-Week Range

₩1193.00 - ₩3355.00

All Time High

₩50300.00